Bevacizumab-containing Regimen for Metastatic Colorectal Cancer Failed to Cytotoxic Treatment

Sponsor
Sixth Affiliated Hospital, Sun Yat-sen University
Study ID
NCT02226289
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    bevacizumab with the latest received cytotoxic regimen

Study Details

Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), combined with fluoropyrimidine-based chemotherapy is now the standard first and second-line treatment for metastatic colorectal cancer. The efficacy of bevacizumab with cytotoxic agents in the third-line treatment of patients with mCRC is still unknown.

Key Dates

First listed
Aug 27, 2014
Start date
Sep 30, 2020
Status verified
Aug 2020
Primary completion
Dec 31, 2020
Completion
Dec 31, 2020

Study Design

Enrollment
46 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: bevacizumab-containing
    bevacizumab with the latest received cytotoxic regimen

Primary Outcome Measure

Response rate [ Time Frame: Baseline and 6 weeks ]

Central Contacts

Related Studies